Endocare Inc

Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2005

20 slides from Endocare's conference presentation, Oct 21, 2005

  1. Slide 1: Endocare, Inc. at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

    Endocare, Inc. C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference October 25, 2005

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements, etc. Statements contained in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements

  3. Slide 3: Topics

    Topics: Our Vision Statement Technology & Products Current Performance & Financials Preview 2006

  4. Slide 4: Vision

    Vision Endocare is a medical device manufacturer focused on improving the health and quality of patients' lives through safe, cost effective, proprietary cryoablation technologies for treating cancerous tissue and tumors, and vacuum therapy for the treatment of erectile dysfunction.

  5. Slide 5: Company Highlights

    Company Highlights Historical procedure growth 33%+ per year Current market penetration is less than 3% Proven and experienced management team Clinically proven technology in prostate cancer Strong IP positioning and patent protection $400 million growing market in prostate cancer $750 million growi

  6. Slide 6: Endocare Technology Groups

    Endocare Technology Groups Vacuum Technology Erectile Dysfunction Cryoablation Technology Urology Renal Cancer Prostate Cancer Radiology Liver Tumors Lung Tumors Bone Pain

  7. Slide 7: Current Cryo Systems (The Razor)

    TM Current Cryo Systems (The "Razor") CryoCare CryoCare TM

  8. Slide 8: CryoProbe (Razor Blades)

    CryoProbe (Razor Blades) Urology Interventional Radiology Features Multiple Probe System Right Angle design CT-compatible Fits under CT Gantry Tumors easily targeted Wide grip handle Features 6 - 2.4 mm CryoProbes 6 - TemProbes Warming Catheter CryoGrid

  9. Slide 9: Urology - Primary Prostate Cancer Population

    Urology - Primary Prostate Cancer Population 2004 Number of Primary Cryotherapy Procedures 5000 Estimated # of All Other Treatments 212000 Source: Health Advances Interviews, Millennium Research Group, CJS Securities and Company estimates. ACS - 2004 Prostate Cancer Diagnosis Estimates Potential Pri

  10. Slide 10: Industry-wide Procedures per Year - Kidney, Liver, Lung & Bone Pain

    0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 2002 2003 2004 2005 2006 2007 2008 2009 2010 Procedures per Year Kidney Procedures Liver Procedures Bone Procedures Lung Procedures Interventional Radiology & Oncology Industry-wide Procedures per Year - Kidney, Liver, Lung & Bone Pain

  11. Slide 11: Urology Business and Interventional Radiology Business

    Urology Business Emerging Growth Clinical Results - Equivalent 10-Year Data Reimbursement Established Community Physician Focus Education & Behavior Change Patient Consumer Early Stage Clinical Results "Proving" Reimbursement Enhanced or Established Academic Center Focus Clinical Demonstration Inter

  12. Slide 12: Endocare Procedure Growth

    Endocare Procedure Growth 1,546 3,554 2,479 Endocare Direct Market Procedure Growth Reflects all Cryo Procedures Completed 2001 - First Half 2005 2001-2004 Actual and 1st Six Months 2005 4,720 6,550 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 2001 2002 2003 2004 6 Months 2005 3,106

  13. Slide 13: Quarterly Procedure Growth

    % Inc OPYQ 62% 90% 44% 47% 26% 27% 50% 60% 48% 55% 17% 25% 41% 25% Q3 2005 1,600+ Projected

  14. Slide 14: Summary Annual Financial Data

    Summary Annual Financial Data

  15. Slide 15: Summary Quarterly Financial Data

    Summary Quarterly Financial Data * 3rd Quarter 2005 Results Not Yet Reported ($000's) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Total revenues 7,382 $ 8,312 $ 8,365 $ 8,626 $ 9,126 $ 9,078 $ * Gross margin % 42.6% 48.1% 48.9% 52.5% 44.5% 49.5% * SG&A expenses 11,179 $ 9,089 $ 6,994 $ 7,699 $ 8,288 $ 7,828 $ * Less Than

  16. Slide 16: Additional & Potential Cash Use

    Additional & Potential Cash Use Q3 2005 S-2 Liquidated Damages $500,000 D&O Carrier Arbitration Settlement $1,000,000 SEC Settlement $750,000 Delinquent State & Local Taxes (Pre-2004) $975,000 Investigation Related Legal Fees $100,000

  17. Slide 17: Why Endocare?

    Clinically proven technology for tissue and tumor ablation. Strong IP and broad market potential. Rapid procedural growth in large expanding markets. Accelerating market acceptance among physicians, academics, patients and payors. Gross margins, net income and operating results are expected to impro

  18. Slide 18: Endocare Comparable Companies Analysis

    Endocare Comparable Companies Analysis - Market and Trading Data ($ in millions)

  19. Slide 19: 2006 Outlook & Assessment

    2006 Outlook & Assessment The issues should be behind us SEC, DOJ... and National Listing occurs Management can focus on Achievement Milestones to Track & Assess: Procedural growth - 35%+ annually Improving gross margins Declining use of cash Potential to expand to new markets

  20. Slide 20: Thank you for your Interest & Consideration

    Thank you for your Interest & Consideration

Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2005 on 6ix